Trialbee Secures Majority Investment from Varsity Healthcare Partners to Accelerate Clinical Trial Patient Recruitment
核心洞察
Trialbee (搜索), a global leader in technology-driven patient recruitment for clinical trials, has secured a majority investment from Varsity Healthcare Partners (搜索) to expand its Honey Platform and enterprise-level recruitment services.
The investment will enable international expansion and development of Trialbee (搜索)'s Omnichannel partner ecosystem to address persistent patient recruitment challenges facing biopharma sponsors.
Over the past year, Trialbee (搜索) screened over 1.5 million patients in 2025 while working with more than 6,000 research sites across 50 countries using 66 languages.
Trialbee (搜索), a global leader in technology-driven patient recruitment for clinical trials, has secured a majority investment from Varsity Healthcare Partners (搜索) (VHP (搜索)) to accelerate its platform capabilities and address mounting challenges in clinical trial enrollment. The investment reflects Trialbee's growing role in delivering superior recruitment outcomes for global biopharma across programs and therapeutic areas.
The funding will enable Trialbee (搜索) to accelerate scale across its platform and services, including continued expansion of its Honey Platform™, international delivery capabilities, enterprise-level recruitment solutions, and Omnichannel partner ecosystem. The investment comes as biopharma sponsors face mounting pressure to address persistent patient recruitment challenges and build infrastructure that can support increasingly complex clinical trial designs.
Expanding Global Reach and Platform Capabilities
Over the past year, Trialbee (搜索) has significantly increased its platform capabilities and global reach. The company introduced sponsor-specific registries within its Honey Platform, strengthened data partnerships to power patient-aligned feasibility and projections, and surpassed 1.5 million patients screened in 2025. The company also worked with more than 6,000 research sites across 50 countries using 66 languages.
"Trialbee (搜索)'s mission is to make clinical research more accessible for every patient, everywhere," said Matt Walz, Chief Executive Officer of Trialbee. "With Varsity as our majority partner — and continued support from MTIP (搜索) and Industrifonden (搜索) — we will scale our innovation with the Honey Platform, expand program-level recruitment to meet customer needs across entire pipelines, and deliver even greater predictability and speed for sponsors, CROs and sites worldwide."
Strategic Partnership and Investment Structure
VHP (搜索) invests in healthcare services and technology companies that enable clinical operations at scale, with a focus on strengthening operating infrastructure and growing established platforms. Industrifonden (搜索) and MTIP (搜索) will participate as minority investors in the transaction, with Stout (搜索) serving as the financial advisor to Trialbee (搜索).
The investment aims to expand Trialbee (搜索)'s technology-driven patient recruitment solutions for clinical trials, enabling the company to better connect patients and sites faster and more precisely. This approach is designed to help biopharma customers enroll clinical trials on time and on budget.
Addressing Industry Challenges
The investment comes at a critical time when sponsors seek to address ongoing challenges in patient recruitment and adapt to complex clinical trial designs. In 2024, Trialbee (搜索) entered a collaboration with Massive Bio (搜索) to leverage its Omnichannel Network and boost access and participant recruitment in clinical trials in the oncology (搜索) and hematology (搜索) fields.
Walz emphasized that the partnership will enable Trialbee (搜索) to "scale our innovation with the Honey Platform, expand programme-level recruitment to meet customer needs across entire pipelines, and deliver even greater predictability and speed for sponsors, CROs and sites worldwide."